Effect of the Mediterranean Diet in Patients Affected by CADASIL and Cerebral Amyloid Angiopathy.

Launched by FONDAZIONE I.R.C.C.S. ISTITUTO NEUROLOGICO CARLO BESTA · Apr 11, 2025

Keywords

ClinConnect Summary

This clinical trial is studying the effects of the Mediterranean Diet on patients with two brain conditions: CADASIL and Cerebral Amyloid Angiopathy (CAA). The first part of the study looks at the eating habits and nutritional health of patients to see how closely they follow the Mediterranean Diet and how that might relate to issues like stroke and memory problems. The second part of the trial will involve participants following a Mediterranean Diet that includes extra virgin olive oil or walnuts, to see if this diet can help reduce the risk of strokes and improve cognitive function.

To be eligible for the trial, participants must be 18 years or older and have a confirmed diagnosis of CADASIL or probable CAA. Everyone in the study will need to agree to share their health and nutrition information anonymously. Those who join can expect to track their eating habits and health over time, as well as receive support and guidance on following the Mediterranean Diet. This research is important as it aims to find ways to improve the health and well-being of individuals with these specific brain conditions.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • The study will include individuals of both sexes aged 18 years or older with a diagnosis of CADASIL (confirmed genetically by the presence of the NOTCH3 gene mutation) or possible/probable CAA (defined according to the Boston 2.0 criteria). All participants must provide informed consent for the use of demographic, clinical, and nutritional data for scientific purposes in an anonymous form
• Exclusion Criteria:
• • na